Search

Your search keyword '"Michels, S."' showing total 745 results

Search Constraints

Start Over You searched for: Author "Michels, S." Remove constraint Author: "Michels, S."
745 results on '"Michels, S."'

Search Results

1. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

6. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

7. Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study

10. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential

11. 1171P A phase II theranostic study with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitors (TKI) and undetectable EGFR T790M (THEROS)

12. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

13. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

14. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

15. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort

16. 1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis

19. EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

20. ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

21. The biological effect of small-scale ROS1 aberrations: An in silico analysis

22. Small-scale ROS1 aberrations: Functional impact and therapeutic potential

23. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort

24. 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

27. Theme 11 - Cognitive and Psychological Assessment and Support.

28. Dynamic Editors for Well-Typed Expressions

31. 1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy

34. FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors

35. Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study

36. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study

38. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study

39. Value of polarisation-sensitive optical coherence tomography in diseases affecting the retinal pigment epithelium

43. EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data

44. Small Cell Lung Cancer - Filling the gap between science and patients

45. KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup

46. FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC

Catalog

Books, media, physical & digital resources